Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „pertuzumab“
Suchtreffer
Begriffe & Kennungen
Phesgo · 4.8 · The safety profile of Phesgo was overall consistent to the known safety profile of intravenous pertuzumab in c
Eintrag öffnenPhesgo · 4.8 · • CLEOPATRA, in which pertuzumab was given in combination with trastuzumab and docetaxel to patients with meta
Eintrag öffnenPoherdy · 4.5 · Five studies evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents, docetaxel, pac
Eintrag öffnenPoherdy · 4.5 · No pharmacokinetic (PK) interactions were observed between pertuzumab and trastuzumab, or between pertuzumab a
Eintrag öffnenPoherdy · 4.8 · 11 In neoadjuvant and adjuvant trials, pertuzumab was administered on the same day as other study treatments i
Eintrag öffnenPoherdy · 4.8 · 8 The safety of pertuzumab has been evaluated in more than 6,000 patients in Phase I, II, and III trials in pa
Eintrag öffnenPoherdy · 4.8 · In addition, ADRs reported in the post-marketing setting are included in Table 2. As pertuzumab was used with
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, a higher incidence of diarrhoea was reported in the Pertuzumab-treated arm (71.2%) comp
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, febrile neutropenia occurred in 12.1% of Pertuzumab-treated patients and 11.1% of place
Eintrag öffnenPoherdy · 4.8 · In the APHINITY trial, the adverse event of rash occurred in 25.8% of patients in Pertuzumab arm vs. 20.3% of
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, 8.4% of patients treated with neoadjuvant Pertuzumab, trastuzumab and docetaxel experi
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, diarrhoea occurred in 45.8% of patients treated with neoadjuvant Pertuzumab, trastuzum
Eintrag öffnenPoherdy · 4.8 · In the NEOSPHERE trial, rash occurred in 40.2% of patients treated with neoadjuvant Pertuzumab, trastuzumab an
Eintrag öffnenPoherdy · 4.8 · In the TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant Pertuzumab + TCH and 20.0%
Eintrag öffnenPoherdy · 4.8 · In the neoadjuvant trial NEOSPHERE, in which patients received 4 cycles of pertuzumab as neoadjuvant treatment
Eintrag öffnenPoherdy · 4.8 · Rash In the pivotal trial CLEOPATRA in metastatic breast cancer, rash occurred in 51.7% of Pertuzumab- treated
Eintrag öffnenPoherdy · 4.8 · Table 2 Summary of ADRs in patients treated with Pertuzumab in clinical trials^, and in the Post-marketing set
Eintrag öffnenPoherdy · 4.8 · Table 2 summarizes the ADRs from the pertuzumab-treated groups of the following pivotal clinical trials: • CLE
Eintrag öffnenpertuzumab
Eintrag öffnenpertuzumab
Eintrag öffnen